Charles River conducts contract studies in an established model of mono-iodoacetate (MIA)-induced joint pain to test the efficacy of novel anti-inflammatory compounds. The injection of MIA, a glycolytic inhibitor, causes behavioral, histological and biochemical changes that resemble human osteoarthritis (OA) and its associated joint pain. The animal model is characterized by biphasic pain behaviors, with an early inflammatory phase followed by a later, less inflammatory phase.
Weight-bearing deficit on the MIA-injected limb is used as an indirect measurement of joint pain. Charles River offers state-of-the-art weight-bearing measurement techniques that allow us to measure use-dependent weight-bearing changes in freely moving animals.